europass Curriculum vitae

PERSONAL INFORMATION

Darius Matusevicius

WORK EXPERIENCE

2012–Present

Clinical assessor

Medical Products Agency (Sweden)

COMP delegate

Rapporteur

PRAC Rapporteur

Central scientific advice (different companies and products for MS, AD, PD, ALS, HD, DMD, epilepsy etc.)

Guideline development (comments for MS, AD and ALS guidelines)

2001–2013

Team Leader/Senior Clinical Research Physician

AstraZeneca (Sweden)

Biochemical biomarker for neurological diseases (MS, AD, PD) team leader

Study physician in phase I and II Clinical studies

Clinical Development program development for Products for PD treatment

1992–1998

Neurologist

Neurological Clinic, Kaunas Academical Clinic (Lithuania)

EDUCATION AND TRAINING

1984–1990

Physician

Kaunas Medical Academy (Lithuania)

1990–1992

Neurologist

Kaunas Medical Academy (Lithuania)

1995–1997

PhD in Neurology

Karolinska Institute (Sweden)

Neuroimmunology

Multiple Sclerosis

Myasthenia Gravis

2008–2009

Diploma in Pharmaceutical Medicine

Karolinska Institute (Sweden)

Drugs in Society

Drugs discovery/ and early development

Pharmacokinetics/Pharmacodynamics and special populations

Applied Statistics in Drug Development

Planning a Clinical trial

Evaluation of Clinical trials & Risk/Benefit

Pharmacoepidemiology

Quality of Life & Health Economy

Outcome Research

Marketing and Drug information

ADDITIONAL INFORMATION

Expertise

Neurology, Neuroimmunology, Pharmaceutical Development, Biochemical biomarker development, Early Clinical Development (Phase I and II);

Multiple Sclerosis, Parkinson Disease, Alzheimers Disease

Publications

1. Ottervald J, Franzén B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellström S, Marko-Vargad G, Végvári A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M and Olsson T. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. Journal of Proteomics 2010; 73: 1117-32.

2. Filion LG. Matusevicius D. Graziani-Bowering GM. Kumar A. Freedman MS. Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis. Clinical Immunology 2003; 106(2): 127-38.

3. Filion LG. Graziani-Bowering G. Matusevicius D. Freedman MS. Monocyte-derived cytokines in multiple sclerosis. Clinical & Experimental Immunology 2003; 131(2): 324-34.

4. Matusevicius D and Freedman MS. Immune system, overview. Encyclopedia of the Neurological Sciences. 2003:633-639.

5. Murzenok PP. Matusevicius D. Freedman MS. Gamma/delta T cells in multiple sclerosis: chemokine and chemokine receptor expression. Clinical Immunology 2002; 103(3 Pt 1): 309-16.

6. Teleshova N. Matusevicius D. Kivisakk P. Mustafa M. Pirskanen R. Link H. Altered expression of costimulatory molecules in myasthenia gravis. Muscle & Nerve 2002; 23(6): 946-53.

7. Ozenci V, Rinaldi L, Teleshova N, Matusevicius D, Kivisakk P and Link H. Metalloproteinases and their inhibitors in multiple sclerosis. J Autoimmun 1999; 12:297-303.

8. Matusevicius D, Kivisäkk P, He B, Navikas V, Fredrikson S and Link H. IL-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Multiple Sclerosis 1999; 5:101-104.

9. Kivisäkk P, Stawiarz L, Matusevicius D, Fredrikson S, Söderström M, Hindmarsh T and Link H. High numbers of perforin mRNA expressing CSF cells in multiple sclerosis patients with gadolinium-enhancing brain MRI lesions. Acta Neurol Scand 1999; 100:18-24.

10. Pelidou S.H., Kostulas N., Matusevicius D., Kivisäkk P., Kostulas V. and Link H. High levels of IL-10 secreting cells are present in blood in cerebrovascular diseases. Eur J Neurol 1999; 6:437-442.

11. Fu-Dong Shi, Li Hu, He Bing, Matusevicius D, Link H. and Ljungren H-G. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur J Immunol 1998; 11:3587-3693.

12. Kivisäkk P, Teleshova N, Özenci V, Huang Y, Matusevicius D, Pirskanen R, Söderström M, Fredrikson S and Link H. No evidence for elevated numbers of mononuclear cells expressing MCP-1 and RANTES mRNA in blood and CSF in multiple sclerosis. J Neuroimmunol 1998; 91:108-112.

13. Kostulas N, Kivisäkk P, Yumin H, Matusevicius D, Kostulas V and Link H. Ischemic stroke is associated with the systemic increase of blood mononuclear cells expressing IL-8 mRNA. Stroke 1998; 29:462-466.

14. Matusevicius D, Kivisäkk P, Navikas V, Tian W-Z, Söderström M, Fredrikson S and Link H. Effects of IFN-β1b (Betaferon) treatment on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. Eur J Neurol 1998; 5:265-275.

15. Matusevicius D, Navikas V, Kivisäkk P, Söderström M, Höjeberg B, Ljungdahl Å, Fredrikson S and Link H. IL-12 and perforin mRNA expression is augmented in blood mononuclear cells in multiple sclerosis. Scand J Immunol 1998; 47:582-590.

16. Tian W-Z, Navikas V, Matusevicius D, Söderström M, Fredrikson S, Link H. In vitro effects of Linomide (roquinimex) affects the balance between pro- and anti-inflammatory cytokines in multiple sclerosis. Acta Neurol Scand 1998; 98:94-101.

17. Kivisäkk P, Matusevicius D, He B, Matell R, Söderström M, Fredrikson S, Link H. Interleukin-15 mRNA expression is upregulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. Clin Exp Immunol 1998; 111:193-197.

18. Kivisäkk P, Tian W-Z, Matusevicius D, Link H, Söderström M. Optic neuritis and cytokines: no

relation to MRI abnormalities and oligoclonal bands. Neurology 1998; 50:217-223.

19. Navikas V, Matusevicius D, Söderström M, Pirskanen R, Fredrikson S, Link H. The phosphodiesterase IV inhibitor rolipram selectively suppresses production of proinflammatory cytokines in blood mononuclear cells from patients with multiple sclerosis. Clin Neuropharmac 1998; 21:236-244.

20. Kivisäkk P, Alm G, Tian W-Z, Matusevicius D, Fredrikson S, Link H. Neutralising and binding anti-interferon-1b (IFN-1b) antibodies during IFN-1b treatment of multiple sclerosis. Multiple Sclerosis 1997; 3:184-190.

21. Navikas V, Martin C, Matusevicius D, Söderström M, Fredrikson S, Link H. Soluble CD30 levels in plasma and cerebrospinal fluid in multiple sclerosis, HIV infection and other neurological disease. Acta Neurol Scand 1997; 95:99-102.

22. Matusevicius D, Kivisäkk P, Navikas V, Xiao B-G, Söderström M, Olsson T, Pirskanen R, Fredrikson S and Link H. Autoantigen-induced IL-13 mRNA expression is increased in blood mononuclear cells in myasthenia gravis and multiple sclerosis. Eur J Neurol 1997; 4:468-475.

23. Matusevicius D, Navikas V, Palasik W, Pirskanen R, Fredrikson S and Link H. TNF-, lymphotoxin, IL-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to AChR is augmented in myasthenia gravis. J Neuroimmunol 1996; 71:191-198.

24. Navikas V, Matusevicius D, Söderström M, Fredrikson S, Kivisäkk P, Ljungdahl Å, Höjeberg B and Link H. Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. J Neuroimmunol 1996; 64:63-69.

25. Matusevicius D, Navikas V, Söderström M, Xiao B-G, Haglind M, Fredrikson S and Link H. Multiple sclerosis: the proinflammatory cytokines lymphotoxin- and tumor necrosis factor- are upregulated in cerebrospinal fluid mononuclear cells. J Neuroimmunol 1996; 66:115-123.

Projects

Memberships

Other Relevant Information